Private Equity Reinvents Its Take On Biopharma
Biopharma offers the best PE returns of any health care sector, but represents only about a third of private equity investment in health care as investors remain wary of high-risk R&D and tend to focus on easier targets, which are in limited supply. As the low-hanging fruit disappears, PE investors are looking at new approaches beyond outright purchases and sorting out opportunities in emerging markets.
You may also be interested in...
IMS Health official says the biologic and biosimilar markets are looming growth areas as small-molecule opportunities decline, but questions about the abbreviated biosimilar pathway linger.
Funded initially in 1996 by private and government sources in Taiwan, Vivo Ventures has emerged as a leader among US-based VCs investing in China. The firm’s partners say its success will come through an intricate web of business development and licensing arrangements between health care companies in China with their counterparts in the US. The strategy has produced results. In the US, specialty pharmaceutical company Sagent Pharmaceuticals went public last year after building a booming business at least partially upon arrangements with China suppliers. In China, Medtronic stepped up in October to acquire Kanghui Medical, an orthopedics company with global vision and connections to privately held US companies.
Now that Japan's Takeda Pharmaceuticals Co. Ltd. is just months away from closing on its €9.6 billion ($13.7 billion) purchase of privately-held Nycomed AS, the Swiss company's investors are planning plenty of changes for the U.S. dermatology business that wasn’t included in the large acquisition.